Reports Q2 revenue $58.88M, consensus $49.4M. “We delivered an outstanding second quarter, achieving profitability in our MRD business with accelerating top- and bottom-line growth,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies (ADPT). “With 42% MRD revenue growth, 37% clonoSEQ volume growth and positive MRD adjusted EBITDA, we’re raising our MRD revenue guidance and lowering total company cash burn targets. We’re executing with discipline, urgency and precision to drive impact in MRD, advance Immune Medicine and create lasting value for patients, partners and shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- COIN, BMNR, RBLX: Cathie Wood Buys Over $54M of Crypto Stocks, Dumps Roblox Stake
- Cathie Wood Buys $69M Worth of Figma Stock on Blockbuster IPO Debut
- Adaptive Biotechnologies price target raised to $13 from $11 at BTIG
- Adaptive, Flatiron Health integrates clonoSEQ MRD testing into OncoEMR
- Craig-Hallum bullish on Adaptive Biotechnologies, initiates with a Buy